» Articles » PMID: 29567340

Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis

Abstract

For patients with acute lymphoblastic leukemia (ALL), allogeneic hematopoietic cell transplantation (alloHCT) offers a potential cure. Life-threatening complications can arise from alloHCT that require the application of sophisticated health care delivery. The impact of country-level economic conditions on post-transplantation outcomes is not known. Our objective was to assess whether these variables were associated with outcomes for patients transplanted for ALL. Using data from the Center for Blood and Marrow Transplant Research, we included 11,261 patients who received a first alloHCT for ALL from 303 centers across 38 countries between the years of 2005 and 2013. Cox regression models were constructed using the following macroeconomic indicators as main effects: Gross national income per capita, health expenditure per capita, and Human Development Index (HDI). The outcome was overall survival at 100 days following transplantation. In each model, transplants performed within lower resourced environments were associated with inferior overall survival. In the model with the HDI as the main effect, transplants performed in the lowest HDI quartile (n = 697) were associated with increased hazard for mortality (hazard ratio, 2.42; 95% confidence interval, 1.64 to 3.57; P < .001) in comparison with transplants performed in the countries with the highest HDI quartile. This translated into an 11% survival difference at 100 days (77% for lowest HDI quartile versus 88% for all other quartiles). Country-level macroeconomic indices were associated with lower survival at 100 days after alloHCT for ALL. The reasons for this disparity require further investigation.

Citing Articles

Increasing access to allogeneic hematopoietic cell transplant: an international perspective.

Rocha V, Fatobene G, Niederwieser D Hematology Am Soc Hematol Educ Program. 2021; 2021(1):264-274.

PMID: 34889391 PMC: 8791161. DOI: 10.1182/hematology.2021000258.


Access to hematopoietic stem-cell transplantation in India.

Kulkarni U, George B J Postgrad Med. 2019; 65(1):1-4.

PMID: 30693869 PMC: 6380131. DOI: 10.4103/jpgm.JPGM_391_18.

References
1.
Knight J, Rizzo J, Logan B, Wang T, Arevalo J, Ma J . Low Socioeconomic Status, Adverse Gene Expression Profiles, and Clinical Outcomes in Hematopoietic Stem Cell Transplant Recipients. Clin Cancer Res. 2015; 22(1):69-78. PMC: 4703514. DOI: 10.1158/1078-0432.CCR-15-1344. View

2.
Metzger M, Howard S, Fu L, Pena A, Stefan R, Hancock M . Outcome of childhood acute lymphoblastic leukaemia in resource-poor countries. Lancet. 2003; 362(9385):706-8. DOI: 10.1016/S0140-6736(03)14228-6. View

3.
Barba P, Burns L, Litzow M, Juckett M, Komanduri K, Lee S . Success of an International Learning Health Care System in Hematopoietic Cell Transplantation: The American Society of Blood and Marrow Transplantation Clinical Case Forum. Biol Blood Marrow Transplant. 2016; 22(3):564-570. PMC: 4965270. DOI: 10.1016/j.bbmt.2015.12.008. View

4.
Majhail N, Mau L, Chitphakdithai P, Payton T, Eckrich M, Joffe S . National Survey of Hematopoietic Cell Transplantation Center Personnel, Infrastructure, and Models of Care Delivery. Biol Blood Marrow Transplant. 2015; 21(7):1308-14. PMC: 4466059. DOI: 10.1016/j.bbmt.2015.03.020. View

5.
Jabo B, Morgan J, Martinez M, Ghamsary M, Wieduwilt M . Sociodemographic disparities in chemotherapy and hematopoietic cell transplantation utilization among adult acute lymphoblastic and acute myeloid leukemia patients. PLoS One. 2017; 12(4):e0174760. PMC: 5383052. DOI: 10.1371/journal.pone.0174760. View